Please login to the form below

Not currently logged in
Email:
Password:

ShangPharma hires Biogen exec

Art Taveras joins as chief scientific officer 

ShangPharma, Art Taveras ShangPharma has hired Biogen Idec's Dr Art Taveras as president and chief scientific officer.

Dr Taveras held several vice president roles at US-based biotech Biogen, including for small molecules drug discovery, chemistry R&D and CMC development.

He now moves to China to head science at ShangPharma, a clinical research organisation (CRO) which employs 2,000 scientists.

"His extensive leadership, strategic and technical experience at the highest levels in pharmaceutical drug discovery and development will be a great asset to the company as it strives to become the preferred small molecules and biologics drug discovery partner for biopharmaceutical companies,” said Michael Hui, chairman and CEO of ShangPharma.

Dr Taveras' career prior to joining Biogen includes senior positions at Alantos Pharmaceuticals and Schering-Plough.

28th October 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics